

Geleitwort

Oncologists taking care of women with breast cancer are confronted with a rapidly expanding portfolio of new, expensive and sometimes toxic targeted drugs. Their „individualized“ prescription requires a steep learning curve of their targets, indications, doses and schedules, and, importantly, their risks versus benefits ratio. This is where this book by Nadia Harbeck et al. brings great value.

Indeed it provides a concise review of the randomized evidence supporting the current use of the new agents, but also describes the ongoing trials that might broaden clinical indications in the future. It gives all the needed information on dosing and scheduling.

In addition, it contains a chapter fully dedicated to the practical management of side effects, both in terms of prevention and treatment. Oncologists of all ages will benefit from this book.

Brussels,
July 2014

**Martine Piccart-Gebhart,
MD, PhD**